Investigational drug · Phase 2
PGN-EDODM1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy 1.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "PGN-EDODM1"
First trial start
2024
Dec 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PGN-EDODM1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy 1
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PGN-EDODM1" as an intervention, largest first.
- An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)Recruiting
PepGen IncIndustry
NCT07220603 · 48 participants (planned) · Start Dec 23, 2025 · Primary completion Jan 2029
Drug: PGN-EDODM1 · For: Myotonic Dystrophy 1
Sites: Calgary, Canada; Ottawa, Canada; Saguenay, Canada
PepGen IncIndustry
NCT06667453 · 24 participants (planned) · Start Dec 10, 2024 · Primary completion Mar 2027
Drug: PGN-EDODM1 · For: Myotonic Dystrophy 1
Sites: Calgary, Canada; Ottawa, Canada; Chicoutimi, Canada · 12 sites in all
- Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1Completed
PepGen IncIndustry
NCT06204809 · 24 participants · Start Dec 12, 2023 · Primary completion Oct 28, 2025
Drug: PGN-EDODM1 for infusion · For: Myotonic Dystrophy 1
Sites: Irvine, California; Palo Alto, California; Atlanta, Georgia · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myotonic Dystrophy 1
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- ATX-01Phase 21 trial
ARTHEx Biotech S.L. · Myotonic Dystrophy 1
- SRP-1003ARO-DM1Phase 21 trial
Sarepta Therapeutics, Inc. · Myotonic Dystrophy 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.